Clinical Research Directory

Inclusion Criteria: * Able to provide written consent * Patient has given permission to give tumor/blood sample for research testing * Histological confirmation of adenocarcinoma, adenosquamous, or small cell carcinoma of the cervix * Known HPV status defined as positive staining for p16 on IHC or DNA ISH for HPV * Willingness to return to enrolling institution (Mayo Clinic Rochester or the University of Minnesota) for follow-up (during the Active Monitoring Phase of the study) or complete blood draws locally using study mail-in kits * Consent to allow blood specimens to be shared with Mayo Clinic study personnel and potential external collaborators for sample analysis * Definitive Chemoradiotherapy for Locally Advanced Disease (FIGO Stage IB2-IIIC) * FIGO 2019 Stage IB2-IIIC or not a surgical candidate * Plan to undergo definitive chemoradiotherapy including external beam radiotherapy, brachytherapy, and chemotherapy Exclusion Criteria: * Other active malignancy =\< 2 years prior to registration. * EXCEPTIONS: Non-melanotic skin cancer * NOTE: If there is a history or prior malignancy, they must not be receiving other specific treatment for cancer * Pregnancy or lactation * Inability on the part of the patient to understand the informed consent to be compliant with the protocol